Press Release | Frontier Medicines

Frontier Medicines to Present Preclinical Data for FMC-242, a Novel Covalent Allosteric PI3Kα-RAS Breaker, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

November 3, 2026/in Press Release, Featured, 2026/by Alejandro Carbajal

November 4, 2026

Frontier Medicines Announces FDA Allowance to Proceed Under an IND for FMC-242, a Novel Covalent Allosteric PI3Kα-RAS Breaker, in Patients with Select Advanced Solid Tumors

October 28, 2026/in Press Release, 2026/by Paul Simpson

October 29, 2026

Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026

October 24, 2026/in Press Release, 2026/by Paul Simpson

October 25, 2026

Frontier Medicines to Present First Clinical Data for FMC-376, an equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026

October 16, 2026/in Press Release, 2026/by Paul Simpson

October 19, 2026

Frontier Medicines Strengthens Leadership Team with Appointment of Three Drug Development Veterans

September 29, 2026/in Press Release, 2026/by Alejandro Carbajal

September 30, 2026

Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors

April 10, 2026/in Press Release, 2026/by Alejandro Carbajal

April 13, 2026

Frontier Medicines Announces Exclusive Licensing Agreement for FMC-220, a First-in-Class Covalent p53 Y220C Activator, with LG Chem, Ltd.

March 31, 2026/in Press Release, 2026/by Paul Simpson

April 1, 2026

Frontier Medicines to Present Findings on PI3Kα-RAS Breaker FMC-242 and AI-Powered Frontier™ Platform at AACR Annual Meeting 2026

March 17, 2026/in Press Release, 2026/by Paul Simpson

March 17, 2026

Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026/in Press Release, 2026/by Paul Simpson

January 7, 2026

Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines

January 5, 2026/in Press Release, 2026/by Paul Simpson

January 5, 2026

Frontier Medicines to Present Preclinical Data for FMC-242, a Novel Covalent Allosteric PI3Kα-RAS Breaker, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Frontier Medicines Announces FDA Allowance to Proceed Under an IND for FMC-242, a Novel Covalent Allosteric PI3Kα-RAS Breaker, in Patients with Select Advanced Solid Tumors

Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026

Frontier Medicines to Present First Clinical Data for FMC-376, an equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026

Frontier Medicines Strengthens Leadership Team with Appointment of Three Drug Development Veterans

Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors

Frontier Medicines Announces Exclusive Licensing Agreement for FMC-220, a First-in-Class Covalent p53 Y220C Activator, with LG Chem, Ltd.

Frontier Medicines to Present Findings on PI3Kα-RAS Breaker FMC-242 and AI-Powered Frontier™ Platform at AACR Annual Meeting 2026

Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines

Our Locations

Boston Office

South San Francisco Office